Regenerex Pharma, Inc.

Regenerex Pharma, Inc. is a U.S.-based pharmaceutical preparations company focused on advanced wound care healing products. Its business centers on proprietary wound-closure technologies, including QBx™, for chronic, acute, and contamination-controlled wound treatment across medical care settings.

0.13

0.13

— Regenerex Pharma, Inc.
%
Advanced wound care technologies45% Proprietary technologies and formulations for chronic, acute, and contaminated wounds.
Wound Closure System protocols20% Clinical protocols and treatment pathways used with the company's wound products.
QBx™ active ingredient platform20% Core biologic ingredient designed to down-regulate proteases and support healing.
Digital wound management tools10% AI-enabled patient tracking and medication support software for wound care programs.
Distribution and commercialization services5% Partner-led commercialization, distributor development, and market access support.

Regenerex sells into healthcare payors and care-delivery organizations that manage chronic and acute wounds, especially...

  • State Medicaid programsprimary

    Buy wound care products and protocols to manage high-cost chronic wound populations at lower total cost.

  • Home health and nursing homesprimary

    Use wound closure products for aging patients with diabetic, pressure, and venous ulcers.

  • Private insurance networkssecondary

    Seek preferred-provider arrangements and reimbursable wound care solutions that improve outcomes.

  • Government healthcare systemssecondary

    Includes VA and correctional facilities that need standardized wound protocols and cost control.

  • International distributorsemerging

    Purchase or distribute the company's products in Asia and the Middle East.

Regenerex is headquartered in Tennessee and also maintains an office in Nevada, with operations organized around U.S...

  • •Headquartered in Gordonsville, Tennessee
  • •Identity office in Las Vegas, Nevada
  • •U.S. Southeast is a key target for Medicaid contracts
  • •Puerto Rico is discussed for federally funded programs
  • •Asia and the Middle East are target export markets
  • •Manufacturing and distribution are largely outsourced

Regenerex is focused on converting its wound-care technologies into reimbursable contracts with state Medicaid...

01
Win reimbursement-backed U.S. contractsshort-term

The business depends on payor access and contracted patient volume to commercialize wound products.

02
Build international distributionmedium-term

Distributor-led expansion can extend the addressable market without heavy owned infrastructure.

03
Differentiate through technology and datamedium-term

Clinical protocols and AI tools can support adoption, adherence, and reimbursement value.

Regenerex is a development-stage healthcare company with no established revenue base, so execution depends on winning...

critical

Going-concern and financing risk

The company needs external capital to fund operations and commercialization before meaningful revenue is established.

Scope
Corporate liquidity and business continuity
Materiality
high
high

Reimbursement and payor access risk

The business model relies on Medicaid, Medicare, and insurer coverage for wound-care adoption.

Scope
U.S. state programs, private insurance, federal programs
Materiality
high
high

Commercialization and adoption risk

Healthcare buyers may be slow to adopt new wound-care protocols without strong clinical and economic proof.

Scope
Hospitals, home health, nursing homes, clinics
Materiality
high
high

Cybersecurity and cash theft risk

A reported bank-account hacking incident shows exposure to fraud and treasury controls.

Scope
Cash management
Materiality
high
medium

Competition risk

The company competes with established wound-care and consumer product companies with scale and distribution.

Scope
Domestic and international wound-care markets
Materiality
medium
Stock-based compensation and warrants
Expense recognition and equity dilution
Purchased intellectual property
Balance sheet carrying value and amortization
Going-concern assessment
Disclosure and investor risk assessment
Lease accounting
Right-of-use assets and lease liabilities

MIMEDX GROUP, INC.

MDXG · Surgical & Medical Instruments & Apparatus

Organogenesis Holdings Inc.

ORGO · Pharmaceutical Preparations

RenovoRx, Inc.

RNXT · Pharmaceutical Preparations

Regen BioPharma Inc

RGBP · Pharmaceutical Preparations

BIOREGENX, INC.

BRGX · Services-Computer Programming, Data Processing, Etc.

REGENERON PHARMACEUTICALS, INC.

REGN · Pharmaceutical Preparations

: 29/04/2026